ContraFect's latest marketcap:
As of 08/02/2025, ContraFect's market capitalization has reached $5,352. According to our data, ContraFect is the 49716th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 5,352 |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -24,138,000 |
| Shares Out | 10.7 M |
| EPS (ttm) | -5.58 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
ContraFect's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/02/2025 | $5,352 | 48554.55% | 49716 |
| 12/26/2024 | $11 | -100% | 48460 |
| 12/29/2023 | $321,144 | -92.34% | 46785 |
| 12/30/2022 | $4.19 M | -95.95% | 45042 |
| 12/31/2021 | $103.45 M | -26.34% | 43007 |
| 12/31/2020 | $140.44 M | 47.58% | 39769 |
| 12/31/2019 | $95.17 M | -21.67% | 37054 |
| 12/31/2018 | $121.5 M | 63.32% | 35650 |
| 12/29/2017 | $74.39 M | 2.24% | 34117 |
| 12/30/2016 | $72.76 M | -44.26% | 32079 |
Company Profile
About ContraFect Corporation
ContraFect Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products to treat life-threatening and drug-resistant infectious diseases in the United States.
Key Programs & Clinical Trials
- Exebacase: A lysin currently in Phase III clinical trials for treating Staphylococcus aureus infections.
- CF-370: An investigational anti-bacterial therapeutic in Phase 1 trials targeting Pseudomonas aeruginosa infections, including ventilator-associated pneumonia, bloodstream infections, and complicated urinary tract infections.
- CF-296: A preclinical-stage engineered lysin for treating biofilm-related infections in prosthetic joints, osteomyelitis, and persistent joint infections (PJI).
Additional Research & Collaborations
- Exploring Exebacase for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in COVID-19 patients.
- License agreement with The Rockefeller University to develop novel lysin candidates against gram-negative pathogens.
Corporate Overview
Founded in 2008 and headquartered in Yonkers, New York, ContraFect Corporation filed for Chapter 7 bankruptcy liquidation on December 4, 2023, in the U.S. Bankruptcy Court for the District of Delaware.
Frequently Asked Questions
-
What is ContraFect's (OTC-CFRXQ) current market cap?As of 08/02/2025, ContraFect (including the parent company, if applicable) has an estimated market capitalization of $5,352 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does ContraFect (OTC-CFRXQ) rank globally by market cap?ContraFect global market capitalization ranking is approximately 49716 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.